Novartis 2Q Revenues: $14.3 billion (-4%) 2Q Earnings: $2.7 billion (flat) YTD Revenues: $28.0 billion (-3%)   YTD Earnings: $5.1 billion (-9%) Comments: Pharmaceutical sales were $8.3 billion (-1%). Recently launched products helped offset the loss associated with the Diovan patent expiration. Lucentis, Gilenya, Afinitor, Tasigna and Galvus grew 8% to $4.1 billion. Currency had a negative impact of 5 percentage points. Alcon sales were up 1% to $2.6 billion in the quarter, driven by strong...